Sign in

CIK 0001425205

  • Accelerated filer

IOVANCE BIOTHERAPEUTICS, INC.

Sign in to watch
Ticker
IOVA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
753254381
Phone
+1 650-260-7120
Business address
825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
Former names
Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 99 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-03-01 WEISER MICHAEL Director Grant or award · Deferred Restricted Stock Unit +100,000 100,000
2024-03-01 MCPEAK MERRILL A Director Grant or award · Deferred Restricted Stock Unit +50,000 50,000
2024-03-01 Dukes Iain D. Director Grant or award · Deferred Restricted Stock Unit +100,000 100,000
2024-03-01 GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Grant or award · Restricted Stock Units +105,470 105,470
2024-03-01 GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Grant or award · Restricted Stock Units +46,875 46,875
2024-03-01 BILINSKY IGOR Chief Operating Officer Grant or award · Restricted Stock Units +105,470 105,470
2024-03-01 BILINSKY IGOR Chief Operating Officer Grant or award · Restricted Stock Units +46,875 46,875
2024-03-01 Bellemin Jean-Marc Chief Financial Officer Grant or award · Restricted Stock Units +105,470 105,470
2024-03-01 Bellemin Jean-Marc Chief Financial Officer Grant or award · Restricted Stock Units +46,875 46,875
2024-03-01 Countouriotis Athena Director Grant or award · Deferred Restricted Stock Unit +50,000 50,000
2024-02-20 MCPEAK MERRILL A Director Purchase +250,000 $9.15 $2.3M 320,150
2024-02-20 Dukes Iain D. Director Purchase +32,000 $9.15 $293K 54,000
2024-02-20 Rothbaum Wayne P. Director Purchase +5,000,000 $9.15 $45.8M 28,067,333
2024-01-16 Vogt Frederick G Interim CEO & General Counsel Option exercise +20,834 105,668
2024-01-16 Vogt Frederick G Interim CEO & General Counsel Shares withheld for taxes −6,530 $8.37 $55K 99,138
2024-01-16 Vogt Frederick G Interim CEO & General Counsel Option exercise · Restricted Stock Units −20,834 83,338
2024-01-16 GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Option exercise +2,813 35,184
2024-01-16 GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Shares withheld for taxes −1,577 $8.37 $13K 33,607
2024-01-16 GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Option exercise · Restricted Stock Units −2,813 11,251
2024-01-16 BILINSKY IGOR Chief Operating Officer Option exercise +2,813 31,444

Page 16 of 23 · 446 trades